Highlights
The multidimensional treatment strategy guided by ABC-AF risk scores did not show a statistically significant reduction in the composite primary outcome of stroke or death compared to conventional clinical management.
The trial was terminated prematurely due to safety signals, specifically a trend toward higher mortality in the ABC-AF strategy arm among patients with higher baseline clinical risk scores.
